checkAd

     2775  0 Kommentare InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology - Seite 3


    globenewswire
    0 Follower
    Autor folgen
    Seite 3 von 3

    Verfasst von globenewswire
    InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology - Seite 3 InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the NetherlandsInflaRx received initial positive human data from its licensee, Beijing Defengrei …